NCT04178863

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

Efficacy of Topical Latanoprost 0.005% Verses Timolol 0.5% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Intuor Technologies, Inc. · Industry
• Sex: All
• Age: 18 Years – 101 Years
• Healthy volunteers: Accepted

Summary

Topical Prostaglandin Analog vs Betablocker - Corneal Biomechanical Evaluation using CATS Tonometer Prism

Detailed description

This clinical trial is a prospective, controlled, study and will be performed at one clinical investigative site in Tucson Arizona1. The purpose of this study is to determine if the device, CATS tonometer prism, measures intraocular pressure significantly differently than the current standard of care tonometer prism (Goldmann) before and after institution of topical prostaglandin analogs (PGA) for glaucoma treatment. Fifty percent of patients will be randomly placed on topical beta blockers as a control. The difference PGAs and beta blockers would be a measurement of the amount of corneal biomechanical changes made due to the PGA controlled for the effect of IOP lowering by the beta -blocker group.

Conditions

• Glaucoma; Drugs

Interventions

Type	Name	Description
DEVICE	CATS Tonometer	latanoprost vs. timolol
DRUG	Latanoprost	latanoprost IOP reduction

Timeline

• Start date: 2018-07-01
• Primary completion: 2019-12-30
• Completion: 2019-12-30
• First posted: 2019-11-26
• Last updated: 2019-11-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study